While [TIMP 2] × [IGFBP7] is FDA authorized as NephroCheck®, for risk assessment of moderate to severe AKI in adult ICUs, it appears to be just one study that addresses the relevance of this marker in cirrhosis, which is not elaborated upon further [58,59]. This evidence concerns the gene IGFBP7 and acute kidney injury.